Shares of BeiGene Ltd. (HKG:6160, SHA:688235) surged nearly 7% in pre-market trading on Tuesday, after the biopharmaceutical company announced that it expects to achieve positive operating income for the full year 2025 in accordance with US GAAP (Generally Accepted Accounting Principles).
The encouraging forecast from BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative cancer medicines, sent a positive signal to investors and sparked a rally in the company's stock. Shares were up 4% in Hong Kong and 4% in Shanghai during Tuesday morning trading session.
BeiGene's projection of positive operating income for 2025 reflects the company's progress and growth prospects in the oncology market. As a leading player in the development of innovative cancer treatments, the company's strong financial performance and positive outlook have fueled investor confidence, driving the stock's upward momentum.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。